Appointment Supports Advancement of Company’s Strategic Priorities and Organizational Growth with Lead Asset Solrikitug in Phase II Trials

Uniquity Bio, a clinical-stage drug development company focused on immunology and inflammation and backed by Blackstone Life Sciences, today announced the appointment of Will Kane as President and CEO. Mr. Kane will support the organization’s strategy and growth as it advances solrikitug, its lead asset, toward the completion of three Phase II trials and preparation to move rapidly into Phase III.

Mr. Kane joins with more than three decades of biopharmaceutical leadership experience and a track record of building high-performing teams, leading transformational change and delivering exceptional business results across a range of therapeutic areas. He succeeds Brian Lortie, co-founder and former CEO, who stepped down from the company in June 2025. Prior to joining Uniquity Bio, Mr. Kane served as president and chief commercial officer at Anthos Therapeutics, which was recently acquired by Novartis, and he has held senior leadership roles at Karuna Therapeutics, BioXcel Therapeutics, Allergan and Pfizer.

Solrikitug — a highly potent monoclonal antibody targeting Thymic Stromal Lymphopoietin (TSLP), a clinically validated driver of inflammatory response — is advancing through separate Phase II trials in asthma, chronic obstructive pulmonary disease (COPD) and eosinophilic esophagitis (EoE). Uniquity is pursuing potential best-in-class efficacy and convenient dose optimization across these conditions. By preventing the binding of TSLP to its receptors, solrikitug has potential utility in a wide array of immunology and inflammation diseases. Uniquity is also in the process of identifying bispecific candidates for clinical testing, combining solrikitug with other key inflammatory targets to enhance efficacy and/or broaden the applicable patient population in specific indications.

“Will’s leadership, combined with his operational and commercial experience, are the right fit for Uniquity at this stage of the organization’s evolution and development,” said Bill Meury, chairman of the Uniquity Bio board of directors. “The company has tremendous potential, with a seasoned leadership team, an exciting asset in development and a real need for solrikitug in several different indications. As I look ahead to the next phase of Uniquity, I am eager to see how this important work makes a difference for people around the world.”

“Uniquity is in a strong position today — clinically, operationally and financially — and Will’s capabilities and expertise will help maximize the success of solrikitug,” said Kiran Reddy, Uniquity Bio board member and senior managing director at Blackstone Life Sciences. “As we move forward, I’d like to also acknowledge founding CEO Brian Lortie for his leadership and vision, which enabled the company to evolve quickly into an influential biotech advancing a very important medicine in a large market.”

“I am incredibly confident in the Uniquity Bio team and the potentially transformative impact of solrikitug as a highly potent and valuable anti-TSLP therapy,” said Will Kane. “I look forward to working alongside this talented team to drive both the strategy and execution that meets this important moment for the company. As we prepare for several key milestones, each step forward brings us closer to getting a much-needed medicine into the hands of millions of people suffering from underserved indications.”

ABOUT UNIQUITY BIO

Uniquity Bio is a clinical-stage drug development company built by biopharmaceutical executives with a proven track record and backed by Blackstone Life Sciences. The company is specifically structured to identify and advance therapeutic programs in immunology and inflammation with the scientific rigor and quality standards of a global pharma company, the operational agility of a biotech startup and a laser focus on improving patients’ lives. Uniquity Bio is actively advancing its immunology and inflammation pipeline with its lead asset solrikitug, a monoclonal antibody in Phase II trials targeting TSLP. The company anticipates delivering best-in-class efficacy and convenient dose optimization in multiple respiratory and gastrointestinal indications with significant unmet needs. For more information, please visit www.uniquity.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250714185639/en/